TScan Therapeutics reported quarterly EPS of -$0.22, matching the Zacks Consensus Estimate and improving from a loss of -$0.26 per share a year ago. The report is broadly in line with expectations and shows modest year-over-year improvement, but it contains no revenue, guidance, or other catalyst details.
TScan Therapeutics reported quarterly EPS of -$0.22, matching the Zacks Consensus Estimate and improving from a loss of -$0.26 per share a year ago. The report is broadly in line with expectations and shows modest year-over-year improvement, but it contains no revenue, guidance, or other catalyst details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
